

SUN PHARMACEUTICAL NEW PRODUCT - 30 DAY REPORT - VERMONT

NDC	63304-0095-30	63304-0096-30	63304-0135-30
Trade Name	Erlotinib Tab 25mg/30ct	Erlotinib Tab 100mg/30ct	Erlotinib Tab 150mg/30ct
Marketing and Pricing Plans	This product (ANDA approval) is being marketed in the generic, multisource space. This product is priced to reflect a discount off of the Reference Drug listed by the FDA. Sun representatives, who are responsible for generic sales, do not promote to health care providers.	This product (ANDA approval) is being marketed in the generic, multisource space. This product is priced to reflect a discount off of the Reference Drug listed by the FDA. Sun representatives, who are responsible for generic sales, do not promote to health care providers.	This product (ANDA approval) is being marketed in the generic, multisource space. This product is priced to reflect a discount off of the Reference Drug listed by the FDA. Sun representatives, who are responsible for generic sales, do not promote to health care providers.
FDA Priority or Breakthrough?	No	No	No
Acquisition Date	N/A	N/A	N/A
Acquisition Cost	N/A	N/A	N/A
Estimated Avg.number of patients a month	Estimated average of patients per month is unknown to Sun Pharma	Estimated average of patients per month is unknown to Sun Pharma	Estimated average of patients per month is unknown to Sun Pharma